Taxus data previewed
This article was originally published in The Gray Sheet
Executive Summary
TAXUS IV reports major adverse event rate of 10.6% after 12 months compared with 19.8% for control, and sustained benefits in diabetics, Boston Scientific says. The paclitaxel-eluting stent will go before FDA panel review Nov. 20 [Editor's note: For information on a live broadcast or videotape of the FDA Circulatory System Devices Panel go to FDAAdvisoryCommittee.com, or contact Julie Robenson at 301-664-7203]...